We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 541

Aventis Pharms., Inc. v. Amino Chems. Ltd.

  • Baker & Hostetler LLP
  • -
  • USA
  • -
  • May 21 2013

On May 20, 2013, in Aventis Pharms., Inc. v. Amino Chems. Ltd., the U.S. Court of Appeals for the Federal Circuit (Newman, Bryson, Reyna) reversed

ALJ Essex denies motion for leave to supplement notice of prior art in Certain Reduced Folate Nutraceutical Products (337-TA-857)

  • Oblon Spivak McClelland Maier & Neustadt LLP
  • -
  • USA
  • -
  • May 10 2013

On May 8, 2013, ALJ Theodore R. Essex issued Order No. 10 denying Respondents Macoven Pharmaceuticals, LLC and Viva Pharmaceuticals, Inc.'s

IP challenges for the personalised medicines industry - gene claims (part 1)

  • Barker Brettell LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • May 9 2013

When you go to the doctor you expect to be asked a lot of questions about your symptoms and your lifestyle, as the doctor builds up a clinical

Allergan, Inc. v. Sandoz Inc.

  • Baker & Hostetler LLP
  • -
  • USA
  • -
  • May 7 2013

On May 1, 2013, in Allergan, Inc. v. Sandoz Inc., the U.S. Court of Appeals for the Federal Circuit (Dyk, Prost, O'Malley) affirmed-in-part and

Myriad: unlocking the deep secrets of DNA and patentability

  • Calfee Halter & Griswold LLP
  • -
  • USA
  • -
  • May 3 2013

My recent tour of the pioneering Global Center for Health Innovation in Cleveland, Ohio reminded me how important DNA is to the future of medicine

Amphastar’s qui tam suit against Aventis shows importance of patents

  • Fish & Richardson PC
  • -
  • USA
  • -
  • May 3 2013

In a recent ground-breaking qui tam ruling, a California federal court denied Aventis Pharma's (a division of Sanofi-Aventis) efforts to dismiss

Genetic technologies settles infringement suit over non-DNA coding technology

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • May 2 2013

Genetic Technologies Ltd. (GTG) has reportedly settled a patent infringement lawsuit filed in late 2012 against PreventionGenetics. While the terms

Some thoughts on Myriad after the Supreme Court argument

  • Robinson Bradshaw & Hinson
  • -
  • USA
  • -
  • May 1 2013

On April 15, the Supreme Court heard oral arguments in Association for Molecular Pathology v. Myriad Genetics. This was another significant

Supreme debate: are human genes patentable?

  • Venable LLP
  • -
  • USA
  • -
  • April 30 2013

On April 15, 2013, tackling an issue of significant importance to the biotechnology and health care industries, the U.S. Supreme Court heard oral

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy